Immunogenicity and safety of two doses of AS03A- adjuvanted inuenza A/H1N1 2009 vaccine (Pandemrix ®) in cancer patients on chemotherapy

Trial Profile

Immunogenicity and safety of two doses of AS03A- adjuvanted inuenza A/H1N1 2009 vaccine (Pandemrix ®) in cancer patients on chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs AS03A (Primary) ; Influenza A virus H1N1 vaccines (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms VACANCE
  • Most Recent Events

    • 28 Jun 2017 New trial record
    • 05 Jun 2017 Results presented at the ASM Microbe 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top